Human antibodies to bet v 1 and methods of use thereof

NZ799705BActive Publication Date: 2026-09-01REGENERON PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
NZ799705
Authority / Receiving Office
NZ · NZ
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-04-24
Filing Date
2018-05-31
Publication Date
2026-09-01
Estimated Expiration
2038-05-31

Smart Images

  • Figure 00000116_0000
    Figure 00000116_0000
  • Figure 00000117_0000
    Figure 00000117_0000
  • Figure 00000118_0000
    Figure 00000118_0000
Patent Text Reader

Abstract

Provided herein are antibodies that bind Fagales allergens, Fagales related allergens, birch pollen, or Bet v 1, compositions comprising the antibodies, nucleic acids encoding the antibodies, and methods of using the antibodies. According to certain embodiments, the antibodies are fully human monoclonal antibodies that bind to Bet v 1. The antibodies are useful for binding Bet v 1 in vivo, thus preventing binding of the allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and / or basophils, thus ameliorating the untoward response to the Fagales allergens in sensitized individuals.
Need to check novelty before this filing date? Find Prior Art